NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

201994 citationsJournal Article

Authors

William G. Wierda · Pharmacyclics (United States)

John C. Byrd · Gilead Sciences (Germany)

Jeremy S. Abramson · Cyclacel Pharmaceuticals (United Kingdom)

S Bilgrami · Moores Cancer Center

Greg Bociek · Solutions Inc. (Japan)

Danielle M. Brander · Moores Cancer Center

Jennifer R. Brown

Abstract

Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter's transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with histologic transformation.

Topics & Keywords

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment

UN Sustainable Development Goals

No poverty

Publication Details

Published in: Journal of the National Comprehensive Cancer Network

Volume 17, Issue 1, pp. 12-20

DOI: 10.6004/jnccn.2019.0002

Field-Weighted Citation Impact: 8.71